Gilead Sciences Inc. is witnessing a notable uptick in its stock price, driven by strategic partnerships and positive market sentiment.
Gilead Sciences Inc. (NASDAQ:GILD) is rising today, reflecting a 1.06% increase in its stock price, closing at CA$147.85. This positive movement comes amidst a broader healthcare sector that has been experiencing some turbulence.
Investor takeaway: The recent partnership with the Pan American Health Organization (PAHO) to enhance access to HIV prevention treatments is a significant factor contributing to Gilead's stock performance, indicating strong growth potential in emerging markets.
Advertisement
Gilead Sciences Inc
GILD.US
GILD.US
Gilead Sciences Inc
WealthAwesomeMarket cap
$190.38B
Div. yield
2.18%
Div. / share
$3.22
52W high
$160.51
52W low
$111.27
1W change
+6.98%
Beta
0.33
Analyst Price Targets
Based on 28 analysts covering GILD · as of Oct 16, 2026
Wall Street analysts forecast GILD stock price to rise 403.2% over the next 12 months.
Consensus
Buy4.32 / 5.00
Avg. Target
C$159.58
+403.2% Upside
Previously C$159.62 on Oct 14, 2026
Current Price
C$31.71
Last close
Analyst Breakdown (28 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GILD's historical volatility
30-Day Vol
23.9%
Annualized
90-Day Vol
28.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$188.14
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$167.02 | C$153.78 – C$181.41 |
| 60 trading days | C$177.27 | C$157.72 – C$199.24 |
| 90 trading days | C$188.14 | C$163.05 – C$217.09 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
1.06% Increase in Stock Price
Gilead's stock has shown resilience with a 1.06% increase, contrasting with the overall decline in the healthcare sector.
Bull case
Gilead's partnership with PAHO is likely to speed up the adoption of its innovative HIV prevention treatment, lenacapavir, across Latin America and the Caribbean. This could boost revenue and expand its market share in these regions.
Bear case
Despite today's gains, ongoing challenges in the healthcare sector and Gilead's profit margin issues could pose risks to its stock performance moving forward.
Advertisement
Strategic Partnership with PAHO
Gilead recently announced a milestone partnership with the Pan American Health Organization (PAHO) to enhance access to its twice-yearly lenacapavir treatment for HIV prevention. This agreement aims to create a regional pathway for adoption across 14 countries in Latin America and the Caribbean, marking a significant step in Gilead's global access strategy.
Market Sentiment and Future Outlook
While Gilead's stock is gaining today, the broader healthcare sector has been under pressure, with several stocks experiencing declines. Investors are closely monitoring Gilead's ability to convert its innovative treatments into sustainable revenue, especially in light of its recent partnership, which could bolster its market presence in underserved regions.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
